Zacharon Pharmaceuticals

About:

Zacharon Pharmaceuticals employs its glycobiology expertise to develop a new class of human therapeutics targeting glycans.

Website: http://www.zacharon.com

Top Investors: National Institutes of Health, Avalon Ventures

Description:

Zacharon Pharmaceuticals is leveraging unique glycobiology expertise to develop an entirely new class of human therapeutics targeting glycans. Zacharon was incorporated in 2004 and has received initial funding through NIH grants and individual investors. Series A financing was more recently provided by Avalon Ventures, a long-standing San Diego-based venture capital firm with a focus on early stage life science companies. With this strong financial backing and innovative drug development platform in place, Zacharon is developing an entirely new class of human therapeutics addressing substantial unmet needs.

Total Funding Amount:

$4.03M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

San Diego, California, United States

Founded Date:

2004-01-01

Contact Email:

info(AT)zacharon.com

Founders:

Number of Employees:

1-10

Last Funding Date:

2012-04-04

IPO Status:

Private

Industries:

© 2025 bioDAO.ai